An object of the invention is to obtain a biotinylated nucleic acid efficiently, by enhancing dissociation efficiency of biotin in the biotinylated nucleic acid and tamavidin 2 in a tamavidin 2-immobilized insoluble carrier. The inventive method for separating a biotinylated nucleic acid includes (1) contacting a sample containing a biotinylated nucleic acid wherein the biotin is bound to the nucleic acid with a insoluble carrier on which tamavidin is immobilized (a tamavidin-immobilized insoluble carrier) to form a complex of the biotinylated nucleic acid and the tamavidin-immobilized insoluble carrier, and (2) separating the biotinylated nucleic acid from the complex in a solution having pH of 7.8 to 9.5 and in the presence of free biotin. The invention also provides a method for separating the biotinylated nucleic acid to which the nucleic acid-binding protein is bound, a method for separating the nucleic acid-binding protein, and a kit for separating the nucleic acid.

An object of the invention is to obtain a biotinylated nucleic acid efficiently, by enhancing dissociation efficiency of biotin in the biotinylated nucleic acid and tamavidin 2 in a tamavidin 2-immobilized insoluble carrier. The inventive method for separating a biotinylated nucleic acid includes (1) contacting a sample containing a biotinylated nucleic acid wherein the biotin is bound to the nucleic acid with a insoluble carrier on which tamavidin is immobilized (a tamavidin-immobilized insoluble carrier) to form a complex of the biotinylated nucleic acid and the tamavidin-immobilized insoluble carrier, and (2) separating the biotinylated nucleic acid from the complex in a solution having pH of 7.8 to 9.5 and in the presence of free biotin. The invention also provides a method for separating the biotinylated nucleic acid to which the nucleic acid-binding protein is bound, a method for separating the nucleic acid-binding protein, and a kit for separating the nucleic acid.

Methods of determining the presence or absence of a target in a sample are provided. Kits for performing the methods described herein are also provided.

Methods of determining the presence or absence of a target in a sample are provided. Kits for performing the methods described herein are also provided.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids fragmented with a transposase enzyme, optionally complexed to an antibody-binding moiety (e.g., an antibody-binding protein) bound to an antibody for at least one chromatin protein, in a biological sample.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids fragmented with a transposase enzyme, optionally complexed to an antibody-binding moiety (e.g., an antibody-binding protein) bound to an antibody for at least one chromatin protein, in a biological sample.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Nucleic acid binding domains are described for use in isolating nucleic acid. Compositions and kits comprising these nucleic acid binding domains are also described. These nucleic acid binding domains may be used in a variety of methods.

An integrated microfluidic chromatin immunoprecipitation assay dramatically improves the collection efficiency of ChIP DNA from cells. Immunoprecipitation of chromatin fragments is conducted in a microfluidic chamber with a large fraction of its volume (e.g., ˜15-40%) occupied by magnetic immunoprecipitation (IP) beads. Oscillating washing of the beads, enabled by, e.g., solenoid valves (controlled by a computer) and high pressure attached to both ends of the microfluidic chamber, effectively removes unbound chromatin and produces high-quality ChIP DNA. ChIP DNA produced by an example device generates excellent results in the subsequent DNA library preparation. The ChIP-seq (i.e., ChIP followed by next-generation sequencing) results match very well with public data generated using much larger cell sample sizes and a conventional approach.